Citius Pharmaceuticals, Inc. CTXR Balance Sheet

Citius pharmaceuticals, inc. (CTXR)

Balance Sheet / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Sep'10
ASSETS
Current Assets:
Cash and cash equivalents
4,339	2,779	7,893	4,510	3,199	7,041	9,184	2,761	5,007	7,370	3,204	198	61	46	294	1,626	3,759	281	676	950	760	817	1,552	0	0	0	0	-	-	-	-	-	-	-	-	-	-
Other receivables
-	-	-	-	-	-	818	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses
53	55	48	46	46	46	57	73	64	110	220	357	282	443	598	394	20	60	60	5	-	-	0	-	-	5	-	-	-	-	-	-	-	-	-	-	-
Cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	2
Total Current Assets
4,392	2,835	7,941	4,557	3,245	7,088	10,060	2,834	5,072	7,481	3,424	556	343	490	892	2,020	3,779	341	736	956	-	-	1,552	-	0	5	-	0	0	0	0	0	0	0	0	0	2
Property and equipment, net
0	0	0	0	1	1	1	1	1	2	3	1	2	3	3	4	5	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease right-of-use asset, net
1,055	1,103	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Assets:
Trademarks
-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	5	5	5	5	5	5	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deposits
57	57	57	-	2	2	2	2	2	2	2	2	2	2	2	2	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	20	0	0	64	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
In-process research and development
19,400	19,400	19,400	19,400	19,400	19,400	19,400	19,400	19,400	19,400	19,400	-	-	-	19,400	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
In-process research and development
-	-	-	-	-	-	-	-	-	-	-	19,400	-	-	-	19,400	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
In-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	19,400	19,400	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deposits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
In-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19,400	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Goodwill
1,586	1,586	1,586	1,586	1,586	1,586	1,586	1,586	1,586	1,586	1,586	1,586	1,586	1,586	1,586	1,586	1,586	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Other Assets
21,043	21,043	21,043	20,986	20,988	20,988	20,988	20,988	20,988	20,988	20,988	21,008	20,988	20,988	21,053	20,988	20,994	-	5	-	-	-	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets
26,492	24,982	28,986	25,544	24,235	28,078	31,050	23,825	26,063	28,473	24,416	21,567	21,334	21,482	21,950	23,013	24,779	346	741	962	765	822	1,557	0	0	5	0	0	0	0	0	0	0	0	0	0	2
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Bank overdrafts
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	0	-	-	-	-	-	-
Accounts payable
1,524	1,547	2,713	2,430	1,926	2,083	1,573	912	1,400	561	602	1,977	1,862	985	909	309	366	458	559	334	343	199	106	1	0	0	11	0	0	0	0	0	0	0	0	0	0
Accrued expenses
149	209	246	158	175	200	181	115	142	616	560	654	1,856	1,847	958	585	1,003	535	8	26	8	0	60	-	-	-	-	3	3	3	4	4	3	3	3	6	0
Accrued compensation
1,031	1,475	1,400	1,205	1,020	1,381	1,198	935	795	1,203	1,063	1,218	1,082	1,010	903	775	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued interest, related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	3	2	2	2	1	1	0	0	0
Accrued interest - related parties
82	78	74	70	65	61	57	54	50	45	42	97	63	44	30	26	-	-	0	0	0	0	25	0	0	0	0	5	1	1	0	0	-	-	-	-	-
Notes payable - related parties
172	172	172	172	172	172	172	172	172	172	172	5,416	-	-	672	172	-	-	-	-	-	-	-	29	24	20	3	51	26	17	17	2	-	-	0	-	-
Operating lease liability
150	146	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Notes payable - related parties
-	-	-	-	-	-	-	-	-	-	-	-	2,022	1,492	-	-	-	-	0	-	-	-	-	-	-	-	-	0	21	21	21	30	27	20	18	13	0
Accrued compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	615	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	772	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Promissory notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	600	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Derivative warrant liability
-	-	-	-	-	-	-	-	-	-	-	581	426	910	1,681	2,947	1,502	872	738	1,716	1,245	1,390	1,450	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Due to related party
-	-	-	-	-	-	-	0	0	17	27	27	27	27	27	37	68	70	70	65	86	56	56	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Liabilities
3,111	3,629	4,607	4,037	3,361	3,900	3,184	2,190	2,561	2,616	2,469	9,973	7,342	6,318	5,183	4,853	4,353	1,937	1,376	2,142	1,683	1,646	2,299	31	25	20	14	61	57	47	45	40	33	26	24	21	0
Operating lease liability - non current
937	976	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities
4,049	4,606	4,607	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Commitments and Contingencies
-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	-	-	-	-	-	-	-
Stockholders' Equity:
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Common stock – $0.001 par value; 200,000,000 shares authorized; 38,078,062 and 28,930,493 shares issued and outstanding at March 31, 2020 and September 30, 2019, respectively
38	30	28	22	18	17	16	10	10	9	8	5	5	74	4	73	71	34	2	33	31	31	30	18	18	18	18	18	18	18	18	18	18	18	18	18	18
Additional paid-in capital
86,972	80,488	80,169	73,655	68,620	68,292	68,107	59,035	58,880	56,813	49,660	36,266	36,242	34,601	34,097	32,833	31,485	8,636	8,403	6,918	6,357	6,107	5,366	62	62	62	62	0	-	-	0	-	-	-	-	-	-
Accumulated deficit
-64,567	-60,142	-55,819	-52,170	-47,764	-44,132	-40,257	-37,410	-35,389	-30,967	-27,721	-24,677	-22,255	-19,512	-17,336	-14,746	-11,130	-10,261	-9,040	-8,132	-7,307	-6,961	-6,138	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained earnings (accumulated deficit)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	111	105	95	95	79	75	65	63	58	51	44	41	39	15
Total Stockholders' Equity
22,443	20,376	24,378	21,507	20,874	24,178	27,865	21,635	23,501	25,856	21,947	11,593	13,992	15,163	16,766	18,160	20,425	-1,590	-635	-1,180	-918	-823	-741	-31	-25	-15	-14	-61	-57	-47	-45	-40	-33	-26	-23	-21	2
Total Liabilities and Stockholders' Equity
26,492	24,982	28,986	25,544	24,235	28,078	31,050	23,825	26,063	28,473	24,416	21,567	21,334	21,482	21,950	23,013	24,779	346	741	962	765	822	1,557	0	0	5	0	0	0	0	0	0	0	0	0	0	2